Bayer Nails Down Deal To Share Ex-U.S. Rights For Wet AMD Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Regeneron includes joint development and commercialization of VEGF-Trap Eye for wet AMD and diabetic macular edema.